EMA Authorised: Camcevi (leuprorelin mesilate) — Accord Healthcare S.L.U.

View source ↗

Summary

The EMA authorised Camcevi containing leuprorelin mesilate for prostatic neoplasms (prostate cancer) in the EU, with Accord Healthcare S.L.U. as the marketing a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• CAMCEVI (leuprolide)

Snippet

Status: Authorised. Therapeutic area: Prostatic Neoplasms. MAH: Accord Healthcare S.L.U.. Decision date: 03/04/2025